Potency Prediction of Covalent Inhibitors against SARS-CoV-2 3CL-like Protease and Multiple Mutants by Multiscale Simulations
2024-11-01
发表期刊JOURNAL OF CHEMICAL INFORMATION AND MODELING
ISSN1549-9596
EISSN1549-960X
卷号64期号:24
发表状态已发表
DOI10.1021/acs.jcim.4c01594
摘要3-Chymotrypsin-like protease (3CLpro) is a prominent target against pathogenic coronaviruses. Expert knowledge of the cysteine-targeted covalent reaction mechanism is crucial to predict the inhibitory potency of approved inhibitors against 3CLpros of SARS-CoV-2 variants and perform structure-based drug design against newly emerging coronaviruses. We carried out an extensive array of classical and hybrid QM/MM molecular dynamics simulations to explore covalent inhibition mechanisms of five well-characterized inhibitors toward SARS-CoV-2 3CLpro and its mutants. The calculated binding affinity and reactivity of the inhibitors are highly consistent with experimental data, and the predicted inhibitory potency of the inhibitors against 3CLpro with L167F, E166V, or T21I/E166V mutant is in full agreement with IC50s determined by the accompanying enzymatic assays. The explored mechanisms unveil the impact of residue mutagenesis on structural dynamics that communicates to change not only noncovalent binding strength but also covalent reaction free energy. Such a change is inhibitor dependent, corresponding to varied levels of drug resistance of these 3CLpro mutants against nirmatrelvir and simnotrelvir and no resistance to the 11a compound. These results together suggest that the present simulations with a suitable protocol can efficiently evaluate the reactivity and potency of covalent inhibitors along with the elucidated molecular mechanisms of covalent inhibition.
关键词Binding energy Molecular docking Structural dynamics Coronaviruses Covalent reaction Dynamics simulation Expert knowledge Hybrid QM/MM Inhibition mechanisms Multi-scale simulation Pathogenics Reaction mechanism Structure based drug designs
URL查看原文
收录类别EI ; SCI
语种英语
资助项目National Natural Science Foundation of China["32071248","22277130","22307133","32301050"]
WOS研究方向Pharmacology & Pharmacy ; Chemistry ; Computer Science
WOS类目Chemistry, Medicinal ; Chemistry, Multidisciplinary ; Computer Science, Information Systems ; Computer Science, Interdisciplinary Applications
WOS记录号WOS:001366395100001
出版者AMER CHEMICAL SOC
EI入藏号20244817447066
EI主题词Coronavirus
EI分类号102.1.2 ; 1106.1 ; 408 Structural Design ; 801.3 Colloid Chemistry
原始文献类型Article in Press
引用统计
正在获取...
文献类型期刊论文
条目标识符https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/452316
专题物质科学与技术学院
物质科学与技术学院_博士生
共同第一作者Tianqing Nie
通讯作者Yechun Xu; Qiang Shao
作者单位
1.School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
2.State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
3.Lingang Laboratory, Shanghai 200031, China.
4.School of Physical Science and Technology, ShanghaiTech University, Shanghai 201210, China.
5.University of Chinese Academy of Sciences, Beijing 100049, China.
推荐引用方式
GB/T 7714
Muya Xiong,Tianqing Nie,Zhewen Li,et al. Potency Prediction of Covalent Inhibitors against SARS-CoV-2 3CL-like Protease and Multiple Mutants by Multiscale Simulations[J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING,2024,64(24).
APA Muya Xiong.,Tianqing Nie.,Zhewen Li.,Meiyi Hu.,Haixia Su.,...&Qiang Shao.(2024).Potency Prediction of Covalent Inhibitors against SARS-CoV-2 3CL-like Protease and Multiple Mutants by Multiscale Simulations.JOURNAL OF CHEMICAL INFORMATION AND MODELING,64(24).
MLA Muya Xiong,et al."Potency Prediction of Covalent Inhibitors against SARS-CoV-2 3CL-like Protease and Multiple Mutants by Multiscale Simulations".JOURNAL OF CHEMICAL INFORMATION AND MODELING 64.24(2024).
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Muya Xiong]的文章
[Tianqing Nie]的文章
[Zhewen Li]的文章
百度学术
百度学术中相似的文章
[Muya Xiong]的文章
[Tianqing Nie]的文章
[Zhewen Li]的文章
必应学术
必应学术中相似的文章
[Muya Xiong]的文章
[Tianqing Nie]的文章
[Zhewen Li]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。